参考文献
PubMed=16780947; DOI=10.1016/j.leukres.2006.05.003Tohda S., Sato T., Kogoshi H., Fu L., Sakano S., Nara N.Establishment of a novel B-cell lymphoma cell line with suppressed growth by gamma-secretase inhibitors.Leuk. Res. 30:1385-1390(2006)
PubMed=20054396; DOI=10.1038/nature08638; PMCID=PMC2845535Davis R.E., Ngo V.N., Lenz G., Tolar P., Young R.M., Romesser P.B., Kohlhammer H., Lamy L., Zhao H., Yang Y.-D., Xu W.-H., Shaffer A.L. 3rd, Wright G., Xiao W.-M., Powell J.I., Jiang J.-K., Thomas C.J., Rosenwald A., Ott G., Muller-Hermelink H.-K., Gascoyne R.D., Connors J.M., Johnson N.A., Rimsza L.M., Campo E., Jaffe E.S., Wilson W.H., Delabie J., Smeland E.B., Fisher R.I., Braziel R.M., Tubbs R.R., Cook J.R., Weisenburger D.D., Chan W.-C., Pierce S.K., Staudt L.M.Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.Nature 463:88-92(2010)
PubMed=21179087; DOI=10.1038/nature09671; PMCID=PMC5024568Ngo V.N., Young R.M., Schmitz R., Jhavar S., Xiao W.-M., Lim K.-H., Kohlhammer H., Xu W.-H., Yang Y.-D., Zhao H., Shaffer A.L. 3rd, Romesser P.B., Wright G., Powell J.I., Rosenwald A., Muller-Hermelink H.-K., Ott G., Gascoyne R.D., Connors J.M., Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B., Fisher R.I., Braziel R.M., Tubbs R.R., Cook J.R., Weisenburger D.D., Chan W.-C., Staudt L.M.Oncogenically active MYD88 mutations in human lymphoma.Nature 470:115-119(2011)
PubMed=23257783; DOI=10.1038/leu.2012.367Wenzel S.-S., Grau M., Mavis C., Hailfinger S., Wolf A., Madle H., Deeb G., Dorken B., Thome M., Lenz P., Dirnhofer S., Hernandez-Ilizaliturri F.J., Tzankov A., Lenz G.MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma.Leukemia 27:1381-1390(2013)
PubMed=23292937; DOI=10.1073/pnas.1205299110; PMCID=PMC3557051Zhang J., Grubor V., Love C.L., Banerjee A., Richards K.L., Mieczkowski P.A., Dunphy C., Choi W.W.-L., Au W.Y., Srivastava G., Lugar P.L., Rizzieri D.A., Lagoo A.S., Bernal-Mizrachi L., Mann K.P., Flowers C.R., Naresh K., Evens A.M., Gordon L.I., Czader M.B., Gill J.I., Hsi E.D., Liu Q.-Q., Fan A., Walsh K., Jima D., Smith L.L., Johnson A.J., Byrd J.C., Luftig M.A., Ni T., Zhu J., Chadburn A., Levy S., Dunson D.B., Dave S.S.Genetic heterogeneity of diffuse large B-cell lymphoma.Proc. Natl. Acad. Sci. U.S.A. 110:1398-1403(2013)
PubMed=25485619; DOI=10.1038/nbt.3080Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.A comprehensive transcriptional portrait of human cancer cell lines.Nat. Biotechnol. 33:306-312(2015)PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.Genome Med. 7:118.1-118.7(2015)
PubMed=26787899; DOI=10.1073/pnas.1524677113; PMCID=PMC4747717Dekker J.D., Park D., Shaffer A.L. 3rd, Kohlhammer H., Deng W., Lee B.-K., Ippolito G.C., Georgiou G., Iyer V.R., Staudt L.M., Tucker H.O.Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1.Proc. Natl. Acad. Sci. U.S.A. 113:E577-E586(2016)
PubMed=27566572; DOI=10.18632/oncotarget.11524; PMCID=PMC5325377Quentmeier H., Pommerenke C., Ammerpohl O., Geffers R., Hauer V., MacLeod R.A.F., Nagel S., Romani J., Rosati E., Rosen A., Uphoff C.C., Zaborski M., Drexler H.G.Subclones in B-lymphoma cell lines: isogenic models for the study of gene regulation.Oncotarget 7:63456-63465(2016)
PubMed=29416618; DOI=10.18632/oncotarget.20378; PMCID=PMC5787470Liu W., Chen J., Tamayo A.T., Ruan C.-G., Li L., Zhou S.-H., Shen C., Young K.H., Westin J., Davis R.E., Hu S.-M., Medeiros L.J., Ford R.J. Jr., Pham L.V.Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma.Oncotarget 9:346-360(2018)
PubMed=29666304; DOI=10.1158/1078-0432.CCR-17-3004Pham L.V., Huang S.-J., Zhang H., Zhang J., Bell T., Zhou S.-H., Pogue E., Ding Z.-Y., Lam L., Westin J., Davis R.E., Young K.H., Medeiros L.J., Ford R.J. Jr., Nomie K., Zhang L., Wang M.Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas.Clin. Cancer Res. 24:3967-3980(2018)
